The ATCA Approach:
Because current medications cannot cure Alzheimer’s or stop it from progressing.
While there is not yet a cure for Alzheimer’s, research continues to unlock new methods to maintain quality of life.
However, at this time, most Care Facilities can only manage the care of the patient as their cognitive decline continues.
Also disappointingly, the five FDA-approved drugs currently available to treat the disease address only it’s symptoms with limited effectiveness. Many non-medication alternatives, including supplements and foods, also exist, with mixed success.
ATCA doesn’t “just care for” our Alzheimer’s patient, ATCA works to “treat” our patients. In the documented 2½ year trial using our patented protocol: up to 76% of the patients either had no further decline or, even better, had improvement in their mild cognitive impairment. Most care is covered by Medicare. Call 404-999-2605 or email us at info@ATCA.Health.
Prescription Treatment Options for Mild to Moderate Alzheimer’s
Current prescription treatment options are not fully understood in mild to moderate Alzheimer’s disease patient groups. Prescription drugs, like galantamine, rivastigmine, and donepezil are cholinesterase inhibitors that prevent the breakdown of acetylcholine — a chemical your brain produces that is likely linked to memory and thinking. No published study directly compares these drugs against each other and researchers do not understand why a patient may respond better to one drug over the other.
Prescription Treatment Options for Moderate to Severe Alzheimer’s
Patients with moderate to severe Alzheimer’s disease may receive a prescription medication memantine, which is an N-methyl D-aspartate (NMDA) antagonist. Researchers believe it works by regulating glutamate, another chemical produced in the brain.
How does ATCA Treat Alzheimer’s or Memory Loss Differently?
According to the National Institute on Aging, There are only five FDA approved drugs to treat Alzheimer’s disease and they are either cholinesterase inhibitors or NMDA antagonists. Alzheimer Treatment Center of America has built upon existing therapeutic advances with new data-driven technology to create a personalized treatment approach that is more successful than anything currently on the market.
- ATCA offers a novel, personalized strategy, driven by an original artificial intelligence algorithm in combination with medical specialists, genetic testing and nutritional guidelines.
- Between visits, the ATCA telemedicine software enables the therapy team to track progress and answer questions. Our clinic specialists, including health coaches, dieticians, and more, are always just a phone call away.
- In addition to traditional remedies, ATCA is constantly integrating the latest tools including non-pharmaceutical components (e.g., supplements), dietary and behavioral changes for optimal healing. Our specialists also track clinical trials and other experimental treatments to remain at the cutting edge of Alzheimer’s treatment.
Alzheimer’s Treatment Center of America offers a breakthrough, evidence-based treatment protocol designed by leading experts in medicine, science, and technology. Our cutting-edge approach has been proven very effective. In the documented 2½ year trial using our patented protocol: up to 76% of the patients either had no further decline or, even better, had improvement in their mild cognitive impairment. Most of this care is covered by Medicare.